JCO Precis Oncol March 2025 PMID 40048671

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.

Lakshmi Rajdev, Gentry G King, Christopher H Lieu, Stacey A Cohen, Shubham Pant, Nataliya V Uboha, Dustin Deming, Midhun Malla, Anup Kasi, Kelsey Klute, Kristen R Spencer, Arvind Dasari, Van K Morris, Gregory Botta, Andrew M Lowy

Full text PDF Download social card

Mentions

Peak: 19 in Mar 2025

across 3 sources since Mar 2025

Extended reach

119,004

potential audience

Total likes

Video views

Mentions per month

Mar 2025 – Jun 2025

Where it's discussed

X / Twitter29 posts
Bluesky1 posts
YouTube1 videos

AI synopsis

What people are saying

Several posts express enthusiasm about the publication, with remarks like 'Glad to see this finally come out,' indicating strong interest and perceived importance. Communications demonstrate positive tones and focus on the publication's role in advancing cancer research, but lack detailed critical analysis, reflecting a moderate level of engagement and impact expectation.

AgreementModerate agreement

Most discussions express support for the importance of the publication, highlighting its potential significance in the field, as seen in posts praising the publication and noting its role in advancing cancer research.

InterestHigh interest

Discussions demonstrate high curiosity and relevance, with comments showing enthusiasm about the topic being finally introduced and its implications for clinical trials.

EngagementModerate engagement

Posts generally reference the content and context of the paper, but do not deeply analyze the methodologies or detailed implications, indicating moderate engagement.

ImpactModerate impact

While some mentions suggest the publication could influence future research and clinical practices, overall perception indicates moderate impact rather than transformative change, evidenced by language that calls it 'Finally coming out' and mentions of su

Abstract in brief

The National Cancer Institute's GI Oncology Circulating Tumor DNA Working Group is exploring how circulating tumor DNA (ctDNA) can be used in clinical trials for gastrointestinal (GI) cancers, but more research is needed to define its role as a primary endpoint.
The group recommends using ctDNA mainly in early-phase (phase II) trials to assess treatment effectiveness and as a noninvasive method for drug development, but its role in late-stage trials as a main outcome still requires more data.
To effectively include ctDNA in trials, researchers need to consider specific disease biological factors, optimize trial design, and conduct prospective studies to confirm whether ctDNA can reliably predict survival outcomes like progression-free or overall survival.]

Read the full abstract

All mentions

Incorporating Circulating Tumor DNA Testing into Clinical Trials in Gastrointestinal Cancers

Dr Philip discusses how circulating tumor DNA testing can be integrated into clinical trials for GI cancers. The focus is on using ctDNA in early-phase trials to evaluate treatment effectiveness and its potential as a…

ASCO Podcasts · Jun 18, 2025 93 views

Lakshmi Rajdev

@luckydoc2 · X